MSLE

Satellos Bioscience Inc.

Nasdaq· Pharmaceutical Preparations· Inc. Z4· CIK 0001421642 Biotech & Drug Discovery

$6.54 +0.12 (+1.87%)

Oct 26 4:00 PM ET · prev $6.42

Market cap

$136.2M

Micro cap

Consensus

Buy

91% Buy or better · 11 analysts

Median target

$22.50

+244% · range $16.00–40.00

1 year

+1.9%

from $6.42 · Oct 28

30 days

−25.8%

from $8.81

52-week range

$5.59–13.01

−50% from high · low Apr 7

Avg volume 20D

70.5K

Sep 29 spike 433.3K

Short interest

97.3K

≈0.5% of shares · −8.0%

Days to cover

1.6

at average volume

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BULLISH 11 reports · 90 days

Balance 0 bearish · 4 bullish · 1 mixed · 6 neutral oldest → newest, height = score

Avg score

·High conf. 7/11

Strongest BULLISH Satellos announced the USPTO issued U.S. Patent No. 12,747,245 with composition of matter claims covering…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 27 Satellos Bioscience reported its 2025 financial results and highligh…
R Sep 24 Satellos announced FDA clearance of its IND application for forazapa…
R Sep 24 Satellos received FDA clearance for its IND application for forazapa…
E Sep 30 FDA: Satellos Announces Completion of Enrollment in BASECAMP Ph…
X Sep 30 Short interest jumps 28.2% to 105.7K
R Sep 30 Satellos Bioscience completed enrollment for BASECAMP, its Phase 2 t…
R Oct 5 Satellos announced the USPTO issued U.S. Patent No. 12,747,245 with…
A Oct 8 Craig-Hallum initiates

Signal stack

Where each data set points today.

InstitutionsMIXED

Q2 2026: 2 added (0 new), 2 trimmed or exited.
AnalystsBULLISH

10 of 11 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.677 → −$0.628 over 90 days. 1 up, 1 down in 30 days.
Short sellersSTEADY

Short interest −8.0% to 97.3K shares. 1.6 days to cover, ≈0.5% of shares.
TrendDOWNTREND

23% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
MILLENNIUM MANAGEMENT LLC	TRIM	152,768	$1.2M
ADAGE CAPITAL PARTNERS GP, L.L.C.	TRIM	150,000	$1.2M
CITADEL ADVISORS LLC	ADD	67,738	$526.7K
UBS Group AG	DOUBLED	781	$6.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts

Buy 91% rate it Buy or better

Strong Buy4Buy6Hold1Sell0Strong Sell0

12-month targets · 6 analysts

$6.54 $16.00 $22.50 $40.00

Price is below the lowest target. Median implies +244%.Targets as of Oct 28, 2026.

Recent actions

Date	Firm	Action	Rating
Oct 8, 2026	Craig-Hallum INITIATE	INITIATE	Buy
Aug 17, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
Jul 9, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
May 18, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy

Earnings setup

Estimates

−$0.63

EPS estimate, this quarter

+7%

estimate change, 90 days

1↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.677

90d

−$0.677

60d

−$0.618

30d

−$0.618

−$0.628

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.63	-$0.93–-$0.44	-1.7%	$0.00
Next Q	-$0.68	-$1.11–-$0.49	-6.1%	$0.00
Current FY	-$2.49	-$3.27–-$2.13	-5.5%	$0.00
Next FY	-$2.61	-$4.82–-$1.32	-4.5%	$0.00